Kevin Dunleavy

Two decades ago, when two genetic mutations were discovered in Asia that gave scientists a better idea of how pain sensations traveled through the body and identified which part of the nervous syst

While Astellas' Izervay and Apellis' Syfovre battle for market share in geographic atrophy (GA) in the United States, both companies are struggling to reach patients in the indication in Europe.

With the specter of the BIOSECURE Act clouding its future, China’s WuXi AppTec sustained its fourth straight period with a year-over-year revenue decline as the contract research, development and m

The FDA has

A small tweak in the dosing regimen of Eli Lilly’s Alzheimer’s disease drug Kisunla has

Sales of Eli Lilly’s diabetes and weight loss drugs fell far short of expectations in the third quarter, leading the juggernaut company to reduce its annual revenue guidance and triggering speculat

With U.S. sales of $392 million in the third quarter, Regeneron's high-dose version of Eylea is closing in on blockbuster sales in its first full year on the market.

Forget about the “ bumpiness ” analysts expected from Madrigal Pharmaceuticals' launch of potential blockbuster Rezdiffra.

Despite its unique ability to block sodium-glucose linked transporter 2 (SGLT2) in the kidneys and SGLT1 in the intestines, Lexicon's Zynquista (sotagliflozin) has had difficulty negotiating regulatory hurdles.

BioNTech reported surprisingly strong sales of its COVID-1